Marinomed Biotech AG 2021 Annual Report with Sustainability Disclosures
The report highlights Marinomed's record revenues of EUR 11.6 million in 2021, representing a 43% increase driven by strong Carragelose sales and a co-development deal with Luoxin Pharmaceutical. The company adapted its Strategy 2025 to focus on high unmet medical needs in virology and immunology, utilizing its Marinosolv and Carragelose platforms. Marinomed also completed a dose-finding trial for Tacrosolv and secured EUR 9.3 million in funding. Additionally, the company moved into its new sustainable headquarters in Korneuburg and was recognized as Austria's Gender Diversity Champion for the second consecutive year.
Company: Marinomed Biotech AG
Sector: Manufacturing
Country: Austria
Year: 2021
Type: Annual Report with Sustainability Disclosures
Pages: 144
Back to company
Marinomed Biotech AG
Annual Report
The report highlights Marinomed's record revenues of EUR 11.6 million in 2021, representing a 43% increase driven by strong Carragelose sales and a co-development deal with Luoxin Pharmaceutical. The company adapted its Strategy 2025 to focus on high unmet medical needs in virology and immunology, utilizing its Marinosolv and Carragelose platforms. Marinomed also completed a dose-finding trial for Tacrosolv and secured EUR 9.3 million in funding. Additionally, the company moved into its new sustainable headquarters in Korneuburg and was recognized as Austria's Gender Diversity Champion for the second consecutive year.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2021
Reporting Period
Jan 1, 2021 - Dec 31, 2021
Fiscal Year
2021
Published
Apr 12, 2022
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Energy Consumption
Renewable Energy
Water Consumption
Women on Board
Women in Management
Employees